Article

High-Sensitivity C-Reactive Protein and Risk of Sepsis

Department of Emergency Medicine, University of Alabama School of Medicine, Birmingham, Alabama, United States of America.
PLoS ONE (Impact Factor: 3.23). 07/2013; 8(7):e69232. DOI: 10.1371/journal.pone.0069232
Source: PubMed

ABSTRACT

Conventional C-reactive protein assays have been used to detect or guide the treatment of acute sepsis. The objective of this study was to determine the association between elevated baseline high-sensitivity C-reactive protein (hsCRP) and the risk of future sepsis events.
We studied data from 30,239 community dwelling, black and white individuals, age ≥45 years old enrolled in the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. Baseline hsCRP and participant characteristics were determined at the start of the study. We identified sepsis events through review of hospital records. Elevated hsCRP was defined as values >3.0 mg/L. Using Cox regression, we determined the association between elevated hsCRP and first sepsis event, adjusting for sociodemographic factors (age, sex, race, region, education, income), health behaviors (tobacco and alcohol use), chronic medical conditions (coronary artery disease, diabetes, dyslipidemia, hypertension, chronic kidney disease, chronic lung disease) and statin use.
Over the mean observation time of 5.7 years (IQR 4.5-7.1), 974 individuals experienced a sepsis event, and 11,447 (37.9%) had elevated baseline hsCRP (>3.0 mg/L). Elevated baseline hsCRP was independently associated with subsequent sepsis (adjusted HR 1.56; 95% CI 1.36-1.79), adjusted for sociodemographics, health behaviors, chronic medical conditions and statin use.
Elevated baseline hsCRP was associated with increased risk of future sepsis events. hsCRP may help to identify individuals at increased risk for sepsis.

Download full-text

Full-text

Available from: Nathan I Shapiro
  • Source
    • "C-reactive protein (CRP) was determined by automated latex-enhanced immunoassay . Elevated baseline CRP (>3.0 mg/l) was used as marker of increased risk of sepsis[29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several lines of evidence support the involvement of the lectin pathway of complement (LP) in the pathogenesis of acute ischemic stroke. The aim of this multicenter observational study was to assess the prognostic value of different circulating LP initiators in acute stroke. Plasma levels of the LP initiators ficolin-1, -2, and -3 and mannose-binding lectin (MBL) were measured in 80 stroke patients at 6 h only and in 85 patients at 48 h and later. Sixty-one age- and sex-matched healthy individuals served as controls. Stroke severity was measured on admission using the National Institutes of Health Stroke Scale (NIHSS). The outcome was measured at 90 days by the modified Rankin Scale (mRS). Ficolin-1 was decreased in patients compared with controls measured at 6 h (median 0.13 vs 0.33 μg/ml, respectively, p < 0.0001). At 48 h, ficolin-1 was significantly higher (0.45 μg/ml, p < 0.0001) compared to the 6 h samples and to controls. Likewise, ficolin-2 was decreased at 6 h (2.70 vs 4.40 μg/ml, p < 0.0001) but not at 48 h. Ficolin-3 was decreased both at 6 and 48 h (17.3 and 18.23 vs 21.5 μg/ml, p < 0.001 and <0.05, respectively). For MBL no difference was detected between patients and controls or within patients at the different time points. In multivariate analysis, early ficolin-1 was independently associated with unfavorable mRS outcome (adjusted odds ratio (OR): 2.21, confidence interval (CI) 95 % 1.11–4.39, p = 0.023). Early ficolin-1 improved the discriminating ability of an outcome model including NIHSS and age (area under the curve (AUC) 0.95, CI 95 % 0.90–0.99, p = 0.0001). The ficolins are consumed within 6 h after stroke implicating activation of the LP. Early ficolin-1 is selectively related to 3-month unfavorable outcome.
    Full-text · Article · Dec 2016 · Journal of Neuroinflammation
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors sought to determine the association between physical inactivity (characterized by exercise and television watching levels) and long-term rates of community-acquired sepsis. Population-based cohort study of 30,183 adult (≥45years) community-dwelling participants. Subjects reported weekly exercise (low=none, medium=1-3 times/week, high=≥4 times/week) and daily television watching (low=<1hour/day, medium=1-3 hours/day, high=≥4hours/day) levels. The authors evaluated the association between exercise, television watching and rates of sepsis, defined as hospital treatment for a serious infection with ≥2 Systemic Inflammatory Response Syndrome (SIRS) criteria. Among 30,183 participants, 1,500 experienced a sepsis event. Reported weekly exercise was: high 8,798 (29.2%), medium 10,695 (35.4%), and low 10,240 (33.9%). Where available, reported daily television watching was: low 4,615 (19.6%), medium 11,587 (49.3%) and high 7,317 (31.1%). Decreased weekly exercise was associated with increased adjusted sepsis rates (high - referent; medium HR 1.02, 95% CI 0.96-1.20; low 1.33, 1.13-1.56). Daily television watching was not associated with sepsis rates. Sepsis rates were highest among those with both low exercise and high television watching levels (HR 1.49, 95% CI: 1.10-2.01). Physical inactivity may be associated with increased long-term rates of community-acquired sepsis.
    No preview · Article · Apr 2014 · Preventive Medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomarker science brings great promise to clinical medicine. This is especially true in the era of technology miniaturization, rapid dissemination of knowledge, and point-of-care (POC) implementation of novel diagnostics. Despite this tremendous progress, the journey from a candidate biomarker to a scientifically validated biomarker continues to be an arduous one. In addition to substantial financial resources, biomarker research requires considerable expertise and a multidisciplinary approach. Investigational designs must also be taken into account, with the randomized controlled trial remaining the "gold standard". The authors present a condensed overview of biomarker science and associated investigational methods, followed by specific examples from clinical areas where biomarker development and/or implementation resulted in tangible enhancements in patient care. This manuscript also serves as a call to arms for the establishment of a truly global, well-coordinated infrastructure dedicated to biomarker research and development, with focus on delivery of the latest discoveries directly to the patient via point-of-care technology.
    Full-text · Article · Sep 2014
Show more